Pharmacies submitting a 340B identifier incur a high administrative burden and financial risk, and NCPA is hoping to do something about it. NCPAs Director of Policy and Regulatory Affairs Steve Postal, as well as NCPA 3040B Task Force members Trent Thiede and Greg Turner, recently joined a roundtable on 340B transparency organized by the Reservoir Communications Group. NCPA focused its discussion on the difficulty of pharmacists identifying 340B claims, both proactively and retroactively, in any hypothetical reform to the 340B program — echoing similar comments that NCPA made to CMS back in March.
NCPA
